Therapeutic Efficacy of Anodonta cygnea and Crayfish Procambarus clarkii Hemolymph Extracts on Sepsis-Induced Acute Liver Injury in Neonate Rats

Abdeljalil Al Shawous,Amel Soliman,Sohair Fahmy,Ayman Mohamed
DOI: https://doi.org/10.3923/ijp.2023.185.196
2023-03-15
International Journal of Pharmacology
Abstract:Background and Objective: In newborns, sepsis is the third highest cause of morbidity and death. The current research intended to assess the efficacy of freshwater mussel Anodonta cygnea and crayfish Procambarus clarkii hemolymph extracts on sepsis-induced liver damage in neonatal rats. Materials and Methods: Twenty-four newborn rats were allocated into four groups at random, control, sepsis and septic rats treated with A. cygnea hemolymph or P. clarkii hemolymph. The researchers looked at the antiseptic mechanisms of A. cygnea and P. clarkii hemolymph extracts. Results: Hemolymph exhibited an in vitro antioxidant and antibacterial activities. The results showed that hemolymph enhanced liver function significantly, as seen by lower liver enzyme activity. Such as aminotransferases as well as the increase in protein content. Anti-inflammatory activity of hemolymph was assessed by the reduction in levels of Cytochrome C, IL-6 and PG-E2. Moreover, the extracts may be able to reduce hepatic oxidative stress by a marked increment in CAT activity as well as a decrease of MDA level. Furthermore, hemolymph therapy helped to correct the aberrant architecture of hepatic tissues caused by polymicrobial infection. Conclusion: Anodonta cygnea and P. clarkii hemolymph extracts attenuated the liver injury that induced by sepsis as it improves liver biomarkers and suppresses reactive oxygen species propagation due to their antibacterial and anti-inflammatory activities.
pharmacology & pharmacy
What problem does this paper attempt to address?